Patent: 10,160,747
✉ Email this page to a colleague
Summary for Patent: 10,160,747
Title: | Compounds and methods for kinase modulation, and indications therefor |
Abstract: | Disclosed are compounds of Formula I(b): ##STR00001## or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R.sup.3, R.sup.4, R.sup.5, each R.sup.7, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof. |
Inventor(s): | Lin; Jack (Hercules, CA), Ibrahim; Prabha N. (Mountain View, CA), Albers; Aaron (San Francisco, CA), Buell; John (San Francisco, CA), Guo; Zuojun (Pasadena, CA), Pham; Phuongly (San Francisco, CA), Powers; Hannah (San Francisco, CA), Shi; Songyuan (Fremont, CA), Spevak; Wayne (Berkeley, CA), Wu; Guoxian (Foster City, CA), Zhang; Jiazhong (Foster City, CA), Zhang; Ying (Fremont, CA), Wu; Jeffrey (Berkeley, CA) |
Assignee: | Plexxikon Inc. (Berkeley, CA) |
Application Number: | 15/460,095 |
Patent Claims: | see list of patent claims |
Details for Patent 10,160,747
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2036-03-16 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2036-03-16 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2036-03-16 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2036-03-16 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2036-03-16 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2036-03-16 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |